X
Private giants & exposure vehicles
Catalent-under-Novo, Samsung Biologics, PolyPeptide, SHL — the manufacturing cap tables without US tickers, and the listed paths in.
The drug-manufacturing supply chain has a financing problem hiding inside its capacity problem: the most strategically central nodes — Catalent, Samsung Biologics, SHL Medical, Daikyo Seiko, PolyPeptide — are private, foreign-listed, or both. US public-market investors cannot buy the choke directly. They buy paths in. This chokepoint maps those paths and is honest about which ones are real exposure and which are storytelling.
Who owns it
The single largest recent change is structural, not operational. Novo Holdings closed its $16.5B all-cash buyout of Catalent on 18 December 2024, delisting it from the NYSE. Critically for ticker-buyers: Catalent now sits inside Novo Holdings — the foundation-controlled entity that is not Novo Nordisk. What Novo Nordisk A/S (NVO) shareholders actually own from that deal is the three fill-finish sites Novo Nordisk bought directly — Anagni (Italy), Bloomington (USA) and Brussels (Belgium) for ~$11B. NVO holders do not own Catalent's CDMO business. Anyone pitching "NVO = own Catalent" is wrong; NVO = own three captive fill-finish plants.
The component layer is where the cleanest listed path exists. West Pharmaceutical (WST) owns 49% of Daikyo Seiko, the private Japanese maker behind Crystal Zenith polymer vials and FluroTec closures, and distributes Daikyo products worldwide exclusively. WST is the verified vehicle into an otherwise unbuyable component giant. For the Swiss and Korean unlisted/foreign names, US access is mostly thin OTC ADR/ordinary lines: Lonza (LZAGY), Siegfried (SGFEF) and PolyPeptide (PLYGF) — thin, unsponsored, and not substitutes for the home lines. Datwyler's US ADR has gone effectively non-trading, so we track it on its SIX Swiss line (DTG.SW).
What breaks it
The physical bottleneck is aseptic fill-finish and drug-delivery components, not molecules. At CPHI Frankfurt, CDMOs unanimously confirmed industry capacity for large-scale biologics drug substance and aseptic fill-finish remains insufficient. GLP-1 device formats — pens, cartridges, prefilled syringes — concentrate demand on a handful of qualified suppliers (West/Daikyo, Stevanato, SHL). Qualification is the moat: a fill line or stopper is locked to a filed drug product for years, so capacity that exists on paper is not fungible. Distinguish announced from operational rigorously — Samsung's Plant 5 (180,000L) went operational April 2025 and is real output; its Plants 6-8 are 2032 completions, i.e. groundbreakings, not 2026 supply.
What forces the reprice
Three tapes. First, the FDA shortage calendar: semaglutide came off the shortage list Feb 2025 and tirzepatide Oct 2024, confirming brand supply caught up — a tailwind for qualified component/fill suppliers and a headwind for compounding. Second, policy: the BIOSECURE Act was enacted 18 December 2025 as Section 851 of the FY2026 NDAA. Be precise — WuXi entities are not yet named on the 1260H list, though committee chairs have recommended adding them; any addition would route work to Western CDMOs (Lonza, Samsung, Siegfried). Third, capacity milestones and prints: Lonza's Vacaville site contributed ~CHF 0.6B in FY2025 with group sales of CHF 6.5B, +21.7% CER.
Be honest about size and earliness
The exposure quality varies wildly. WST is a real, liquid, audited $3B-revenue NYSE name with a verified 49% Daikyo stake — genuine, ownable exposure. STVN is similar (NYSE, EUR 1.186B FY2025 revenue, GLP-1 ~19-20% of sales). NVO is a megacap whose link to this choke is three captive plants — a rounding error against its drug P&L, so do not buy NVO for the fill-finish exposure. The OTC lines (LZAGY, SGFEF, PLYGF) are technically buyable but thin and unsponsored; the home listings are where price discovery happens (Datwyler, whose US ADR has gone dark, is tracked on its SIX line DTG.SW). And the two most central nodes — Catalent and Samsung Biologics — have no clean US ticker at all: Catalent is buried in unlisted Novo Holdings, and Samsung Biologics trades only in Korea (207940.KS) with no US ADR. This chokepoint is structurally under-investable from a US brokerage account, and saying otherwise would be the failure mode. Map the plants and the qualified-supplier positions; respect that the cap table mostly lives offshore. None of this is investment advice.
Who owns the choke
Daikyo Seiko, Ltd.
Daikyo Seiko is the private Japanese manufacturer of Crystal Zenith cyclic-olefin-polymer vials/syringes, FluroTec film-laminated elastomeric closures and PLASCAP seals used in injectable biologics and cell/gene therapies. West holds 49% of the equity and a technology cross-license; Amgen and others have selected Daikyo CZ for commercial products.
- Bull
- Daikyo's Crystal Zenith polymer vials, FluroTec closures and PLASCAP seals are designed into commercial biologics like Amgen's, a private chokepoint accessible via West's 49% stake.
- Bear
- As a private Japanese maker, exposure comes only diluted through West Pharmaceutical's 49% equity stake rather than any direct tradable line.
Datwyler Holding AG
FY2025 group revenue CHF 1,100.5M with 3.1% organic growth; Healthcare Solutions makes system-critical elastomer closures for injectable drug containers. Expanded an ISO Class 7 cleanroom for coated stoppers in India (April 2025) and introduced low-extractable Omniflex ready-to-use stoppers for mRNA/mAb drugs. The US OTC ADR (DATWY) is effectively non-trading, so the SIX Swiss line (DTG.SW, CHF) is the reference quote.
- Bull
- Datwyler's Healthcare Solutions makes system-critical elastomer closures, expanding coated-stopper cleanroom capacity in India and launching low-extractable Omniflex stoppers for mRNA and mAb drugs.
- Bear
- FY2025 organic growth was just 3.1%, and with the US OTC ADR effectively non-trading the only live quote is the Swiss line (CHF) — not reachable from most US brokerages.
Lonza Group AG (unsponsored ADR)
Lonza's Stein, Switzerland complex performs large-scale commercial biologics filling across vials (liquid and lyophilized), prefilled syringes and cartridges, and is adding a contained ADC filling line targeted to open in 2027. Drug Product was a cited 2025 growth driver. LZAGY is an unsponsored ADR representing one-tenth of a Swiss-listed share.
- Bull
- Lonza spans five chokepoints with its Stein commercial filling complex, a 2027 ADC line, Drug Product as a 2025 growth driver, and CHF6.5bn FY2025 sales with a raised 2026 outlook.
- Bear
- US access is only an unsponsored ADR representing one-tenth of a Swiss share, and broad CDMO exposure leaves it dependent on continued capacity demand it is funding ahead.
Novo Nordisk A/S
Vertically integrated the choke: Novo Holdings bought Catalent for ~$16.5B and Novo Nordisk took three sterile filling sites — Bloomington (IN), Anagni (IT), Brussels — for $11B, and is adding a second $4.1B fill-finish plant at Clayton, NC. The Bloomington site has begun filling Wegovy pens but carries an FDA OAI classification, a warning letter, and an eight-observation Form 483 after an April 2026 re-inspection.
- Bull
- Novo Nordisk vertically integrated the fill-finish choke via Catalent, taking three filling sites for $11B and adding a second $4.1B Clayton plant to secure GLP-1 capacity.
- Bear
- The Bloomington site carries an FDA OAI classification, a warning letter and an eight-observation 483 after April 2026 re-inspection, a live regulatory overhang on the integration.
PolyPeptide Group AG
PolyPeptide is a focused peptide/oligonucleotide API CDMO with large metabolic-disease (GLP-1) exposure. It started new large-scale solid-phase peptide synthesis capacity at Braine-l'Alleud, Belgium in December 2024 (ramping through 2025) and announced a EUR 100M doubling of SPPS capacity at Malmo, Sweden in January 2025; the Braine ramp was estimated to lift revenue ~30%.
- Bull
- PolyPeptide is a focused peptide/oligo CDMO with heavy GLP-1 exposure, ramping new Braine SPPS capacity estimated to lift revenue ~30% and doubling Malmo capacity with EUR100M.
- Bear
- Watch-tier exposure via a US OTC ADR ties the story to a single ramp executing on schedule and to sustained GLP-1 peptide demand.
Siegfried Holding AG
Swiss API-focused CDMO (founded 1873) developing and manufacturing active ingredients; expanded its US footprint with an early-phase CDMO site in Grafton, Wisconsin (from Curia, 2024) and the more material January 2026 acquisitions of Noramco/Purisys/Extractas (closing expected late 2026). Quoted in the US on OTC as SGFEF, a foreign-ordinary line.
- Bull
- Siegfried is a Swiss API CDMO expanding its US footprint via Grafton and the more material Noramco/Purisys/Extractas acquisitions, positioning it across API reshoring demand.
- Bear
- The key 2026 acquisitions only close late-2026 and exposure is via a foreign-ordinary OTC line, leaving the reshoring catalyst unrealized for this watch-tier name.
Stevanato Group S.p.A.
Stevanato makes prefilled syringes (Nexa, its fastest-growing product), EZ-fill vials and cartridges for biologics and GLP-1 drugs. FY2025 revenue was EUR 1.186B (+7%, +9% constant currency), with GLP-1s ~19-20% of sales and GLP-1 revenue up >50% y/y; its Fishers, Indiana plant is being built as the North American high-value hub, reaching full productivity in 2028.
- Bull
- Stevanato's Nexa syringes, EZ-fill vials and cartridges sit across three chokepoints, with FY2025 revenue up 7% and GLP-1 revenue up >50% as its Fishers hub builds out.
- Bear
- The Fishers North American hub only reaches full productivity in 2028, so near-term margins absorb ramp costs ahead of the high-value capacity coming online.
West Pharmaceutical Services, Inc.
FY2025 net sales of $3.074B (+6.3%); high-value-product components (NovaPure, FluroTec, Westar coated stoppers/plungers) were 48% of net sales (Q4 2025/Q1 2026) and grew ~20.3% reported (~15% organic) in Q4 2025, driven by GLP-1 and Annex-1 ready-to-use conversion. Q1 2026 net sales jumped 21.1% to $844.9M with EPS of $2.13. Holds a 49% equity stake in FluroTec-maker Daikyo Seiko.
- Bull
- West is the textbook elastomer choke, with high-value NovaPure/FluroTec/Westar components 48% of sales growing ~20% in Q4 on GLP-1 and Annex-1 ready-to-use conversion.
- Bear
- Growth leans heavily on sustained GLP-1 volumes and Annex-1 conversion timing, so any slowdown in those demand drivers would pressure the high-value mix.
Catalyst calendar
- 2026-08-04Stevanato Group Q2 2026 resultsmediumQuantifies GLP-1 device-format demand (Nexa syringes, EZ-fill) and the Fishers, Indiana ramp — the clearest US-listed read on whether fill-finish component capacity is tightening or easing.
- 2026-08-05Novo Nordisk H1 2026 financial resultsmediumCompany-confirmed 07:30 CEST print that details utilization of the three acquired Catalent fill-finish sites and remaining semaglutide/Wegovy supply constraints — the captive end of the fill-finish choke.
- 2026-10-22West Pharmaceutical Q3 2026 resultsmediumReads through to component (stopper/Crystal Zenith) demand and the 49%-owned Daikyo Seiko affiliate — the most central US-listed proxy for the injectable drug-delivery component chokepoint.
- 2026-10-06CPHI Worldwide 2026 (Oct 6-8)lowThe global pharma-manufacturing supply-chain meeting where CDMO capacity signals (biologics drug substance, aseptic fill-finish) and BIOSECURE re-shoring intent are set — directly drives the supplier-qualification choke this vertical tracks.